Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hepato Cellular Carcinoma × durvalumab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 45 Lung Neoplasms 29 Carcinoma, Hepatocellular 20 Small Cell Lung Carcinoma 17 Urinary Bladder Neoplasms 12 Liver Neoplasms 10 Biliary Tract Neoplasms 10 Breast Neoplasms 8 Neoplasms 7 Stomach Neoplasms 5 Neoplasm Metastasis 5 Colorectal Neoplasms 5 Cholangiocarcinoma 5 Carcinoma, Transitional Cell 5 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Non-Muscle Invasive Bladder Neoplasms 4 Carcinoma 4 Squamous Cell Carcinoma of Head and Neck 3 Neoplasms by Site 3 Endometrial Neoplasms 3 Adenocarcinoma Of Esophagus 3 Adenocarcinoma 3 Thoracic Neoplasms 2 Respiratory Tract Neoplasms 2 Respiratory Tract Diseases 2 Pathologic Complete Response 2 Oropharyngeal Neoplasms 2 Mouth Neoplasms 2

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07489976 2026-03-27

IIT2025-03-YANG-LIFT-HCC

Cedars-Sinai Medical Center

Phase 2 Recruiting

Hepato Cellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡